David C. Myles sold $3.1M of OLMA
CH. DISCOV. & NON-CLIN DEV OFF at Olema Pharmaceuticals, Inc.. 110,000 shares at an average of $28.25, traded Jan 12, 2026, filed Jan 14, 2026.
Score components
- +15RoleOfficer
- +25Trade size$3.1M at market
- +20Share of holdings soldSold 71% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -21.5%, 3m -42.7%, 6m -58.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001831216-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -10,000 | $28.34 | $283k | 144,846 | Jan 14, 2026 |
| Jan 13, 2026 | MOption exercise Common Stock | +50,000 | $4.87 | $244k | 592,761 | Jan 14, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock | -49,800 | $27.60 | $1.4M | 542,961 | Jan 14, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock | -200 | $28.49 | $5,698 | 542,761 | Jan 14, 2026 |
| Jan 14, 2026 | MOption exercise Common Stock | +50,000 | $4.87 | $244k | 592,761 | Jan 14, 2026 |
| Jan 14, 2026 | SOpen-market sale Common Stock | -14,997 | $28.60 | $429k | 577,764 | Jan 14, 2026 |
| Jan 14, 2026 | SOpen-market sale Common Stock | -35,003 | $28.99 | $1.0M | 542,761 | Jan 14, 2026 |
| Jan 13, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 100,000 | Jan 14, 2026 |
| Jan 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 50,000 | Jan 14, 2026 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $291k 25,000 shares | -3% | |
| 44Moderate | OLMAsell Olema Pharmaceuticals, Inc. | Shawnte Mitchell CHIEF LEGAL OFFICER | $952k 40,000 shares | -267% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $269k 10,000 shares | -1% | |
| 40Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $102k 3,489 shares | -0% | |
| 65Notable | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $3.0M 103,822 shares | -43% | |
| 39Weak | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $82k 2,881 shares | -0% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Ian T Clark director | $7.9M 264,800 shares | -100% | |
| 55Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $1.6M 51,000 shares | -8% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Naseem Zojwalla Chief Medical Officer | $7.5M 269,509 shares | -155% | |
| 27Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $205k 25,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.